Protective effect of tumor necrosis factor-α against subsequent endotoxemia in mice is mediated, in part, by interleukin-10

Critical Care Medicine

Volumn 29, Issue 9, 2001, Pages 1761-1766

  Murphey, E D ^a   Traber, D L ^a  

^a SHRINERS HOSPITALS FOR CHILDREN   (United States)

Author keywords

Cytokines; Endotoxin shock; In vivo animal model; Inflammation; Interleukin 10; Rodent; Tolerance; Tumor necrosis factor

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 10 ANTIBODY; LIPOPOLYSACCHARIDE; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CROSS TOLERANCE; ENDOTOXEMIA; EXPERIMENTAL MODEL; FEMALE; HEMODYNAMICS; INFLAMMATION; MORTALITY; MOUSE; NONHUMAN; PERITONEUM LAVAGE; PRIORITY JOURNAL; PROTECTION; SEPTIC SHOCK;

EID: 0034840773     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200109000-00018     Document Type: Article

References (58)

1. A critical evaluation of new agents for the treatment of sepsis
2. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy
3. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality
4. Pattern of cytokines and pharmacomodulation in sepsis induced by cecal ligation and puncture compared with that induced by endotoxin
5. Shock and tissue injury induced by recombinant human cachectin
6. Anti-tumor necrosis factor antibody treatment of recurrent bacteremia in a baboon model
7. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial
8. INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis
9. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis
10. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein
11. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis
12. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection
13. Treatment with recombinant human tumor necrosis factor-alpha protects rats against the lethality, hypotension, and hypothermia of gram-negative sepsis
14. Single-dose tumor necrosis factor protection against endotoxin-induced shock and tissue injury in rats
15. Pretreatment with recombinant murine tumor necrosis factor alpha/cachectin and murine interleukin 1 alpha protects mice from lethal bacterial infection
16. Prevention and treatment of endotoxin and sepsis lethality with recombinant human tumor necrosis factor
17. Pretreatment with a low dose of tumor necrosis factor attenuates the morbidity and mortality induced by continuous infusion of endotoxin in pigs
18. Induction of MnSOD gene expression in a hepatic model of TNF-alpha toxicity does not result in increased protein
19. Tolerance of rats to hyperoxia. Lung antioxidant enzyme gene expression
20. Anti-death properties of TNF against metabolic poisoning: Mitochondrial stabilization by MnSOD
21. Tolerance of rats to hyperoxia. Lung antioxidant enzyme gene expression
22. Neonatal hypersusceptibility to endotoxin correlates with increased tumor necrosis factor production in mice
23. Mn and Cu/Zn SOD expression in cells from LPS-sensitive and LPS-resistant mice
24. Neutralization of IL-10 increases lethality in endotoxemia. Cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor
25. Anti-inflammatory cytokine profile and mortality in febrile patients
26. Compartmentalized cytokine production within the human lung in unilateral pneumonia
27. Perioperative pattern of peritoneal interleukin 8, tumor necrosis factor-alpha, and granulocyte elastase release in human secondary peritonitis
28. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes
29. Regulation of interleukin-10 release by tumor necrosis factor in humans and chimpanzees
30. Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis
31. IL-4 and IL-13 modulate IL-10 release in endotoxin-stimulated murine peritoneal mononuclear phagocytes
32. Interleukin-10 upregulates tumor necrosis factor receptor type-II (p75) gene expression in endotoxin-stimulated human monocytes
33. The effects of interleukin-10 on interleukin-1 receptor antagonist and interleukin-1 beta production in human monocytes and neutrophils
34. Interleukin 10 protects mice from lethal endotoxemia
35. Interleukin-10 prevents early cytokine release in severe intraabdominal infection and sepsis
36. IL-10 improves lung injury and survival in Pseudomonas aeruginosa pneumonia
37. Effects of IL-10 on systemic inflammatory responses during sublethal primate endotoxemia
38. A randomized, controlled trial of IL-10 in humans
39. Interleukin-4 and -10 exacerbate candidiasis in mice
40. Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia
41. Interleukin-10 impairs host defense in murine pneumococcal pneumonia
42. SDZ MRL953, a novel synthetic lipid A analogue, induces tolerance to the lethal effects of endotoxin and enhances nonspecific immunity
43. Enhanced phagocytosis and bacterial activity of hepatic reticuloendothelial system during endotoxin tolerance
44. Beneficial effect of liposome-encapsulated muramyl tripeptide in experimental septicemia in a porcine model
45. Interleukin 10 reduces mortality from severe peritonitis in mice
46. What is the role of interleukin 10 in polymicrobial sepsis: Antiinflammatory agent or immunosuppressant?
47. Inhibition of lipopolysaccharide-induced signal transduction in endotoxin-tolerized mouse macrophages: Dysregulation of cytokine, chemokine, and toll-like receptor 2 and 4 gene expression
48. LPS induces late cardiac functional protection against ischemia independent of cardiac and circulating TNF-alpha
49. Role of endogenous cytokines in endotoxin- and interleukin-1-induced pulmonary inflammatory response and oxygen tolerance
50. Induction of lethal shock and tolerance by Porphyromonas gingivalis lipopolysaccharide in D-galactosamine-sensitized C3H/HeJ mice
51. Mechanism of endotoxin desensitization: Involvement of interleukin 10 and transforming growth factor beta
52. Regulation of acute lung inflammatory injury by endogenous IL-13
53. Interleukin-4-mediated inhibition of nitric oxide production in interferon-gamma-treated and virus-infected macrophages
54. Indomethacin or IL-10 neutralization can reverse the protective effect of TNFa pretreatment against endotoxemia
55. Therapeutic immunomodulatory approaches for the control of systemic inflammatory response syndrome and the prevention of sepsis
56. Endotoxin-induced eicosanoid production by equine vascular endothelial cells and neutrophils
57. Blockade of prostaglandin products augments macrophage and neutrophil tumor necrosis factor synthesis in burn injury
58. Cyclooxygenase inhibitors enhance tumour necrosis factor production and mortality in murine endotoxic shock